Pandhi 2014.

Methods	Design: randomised, placebo‐controlled, parallel‐group trial
Participants	Number assigned: 70 children and adults (macrolide n = 35, placebo n = 35) Age in years (mean ± SD): macrolide: 23.00 ± 8.96, placebo: 23.66 ± 8.35 Setting: secondary care
Interventions	Indication: pityriasis rosea Type of macrolide: azithromycin Route: per oral Dose per day: 500 mg (maximum) Duration of treatment: 5 days Total treatment dose: 2500 mg (maximum)
Outcomes	Adverse events stated as an outcome in trial registration/protocol/paper: yes Adverse events ascertainment: participant asked Adverse events: data reported Antimicrobial resistance: not reported Death: not reported
Funding sources	None stated.
Notes	Concomitant medication: unclear
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated randomisation
Allocation concealment (selection bias)	Low risk	Central allocation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Identical‐appearing placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants and clinicians blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low dropout
Selective reporting (reporting bias)	Low risk	Adverse events stated as an outcome, standardised ascertainment, and adverse events reported.
Other bias	Low risk	None were identified.